James Kidd, MD
Allergy & Immunology · Baton Rouge, LANPI 1407935281
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,574 and has fallen 63.2% since, to $579 in 2025.
Across 286 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Sanofi$854
- Regeneron Healthcare Solutions, Inc.$844
- Novartis$619
- AstraZeneca$588
- CSL Behring$447
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,80999%
- Education$821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 50 | $1,093 |
| Sanofi | 30 | $854 |
| Regeneron Healthcare Solutions, Inc. | 37 | $844 |
| Novartis | 32 | $619 |
| AstraZeneca | 24 | $588 |
| CSL Behring | 18 | $447 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $432 |
| Genentech USA, Inc. | 12 | $330 |
| Pfizer | 10 | $263 |
| Amgen | 3 | $236 |
| Shire North American Group Inc | 9 | $180 |
| Teva Pharmaceuticals USA, Inc. | 8 | $153 |
| Grifols USA, LLC | 7 | $143 |
| Kaleo, Inc. | 7 | $127 |
| Boehringer Ingelheim | 5 | $85 |
| Sanofi-aventis U.S. LLC | 1 | $82 |
| Aimmune Therapeutics, Inc. | 3 | $69 |
| Galderma Laboratories, L.p. | 2 | $53 |
| LEO Pharma Inc. | 3 | $52 |
| Octapharma USA, Inc. | 1 | $39 |
| Biocryst US Sales Co., LLC | 2 | $34 |
| Alk-abello, Inc | 2 | $33 |
| Bio Products Laboratory USA, Inc. | 1 | $32 |
| Tersera Therapeutics LLC | 1 | $29 |
| ADMA Biomanufacturing LLC | 1 | $22 |
| Optinose US, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,891 in reported general payments places this provider in the 65th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 45 | $136,555 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $34,465 |
| DuleraMometasone/Formoterol | 14 | $7,107 |
| Arnuity ElliptaFluticasone Furoate | 18 | $6,855 |
| Epinephrine | 22 | $4,459 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,151 |
| Montelukast Sodium | 125 | $1,866 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,714 |
| Hydroxyzine Hcl | 52 | $1,241 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $640 |
| Ipratropium Bromide | 18 | $459 |
| Triamcinolone Acetonide | 20 | $315 |
| Azelastine Hcl | 21 | $312 |
| Levocetirizine Dihydrochloride | 20 | $308 |
| Hydrocortisone | 13 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $1,093 | $41,32049 claims |
| MerckDulera | $15 | $7,10714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in Baton Rouge
- Louis GaudinBaton Rouge$9K
- Kesler BourgoyneBaton Rouge$6K
- Joseph RedheadBaton Rouge$4K
- Jo ReedBaton Rouge$698
- John ErffmeyerBaton Rouge$63
- David KaufmanShreveport$678K
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
- Brice RolstonCovington$54K
- Caroline CapertonShreveport$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.